Bildkälla: Stockfoto

Alzecure: Reports Positive Phase I “MAD” results with ACD856 - Redeye

Redeye endorses the positive outcome from Alzecure’s phase I “MAD” study with drug candidate ACD856 and slightly raise our base case.

Redeye endorses the positive outcome from Alzecure’s phase I “MAD” study with drug candidate ACD856 and slightly raise our base case.
Börsvärldens nyhetsbrev
ANNONSER